All In Biotech

Drug Trial Radar · NCT05669755

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 7,101 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

7,101

Actual

Start

Mar 1, 2023

Primary completion

Sep 1, 2027

Study completion Oct 14, 2027

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jan 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for up to 4.5 years.

Conditions

  • Cardiovascular Disease

Interventions

  • CagrilintideDrug

    Participants will receive cagrilintide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.

  • SemaglutideDrug

    Participants will receive semaglutide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.

  • PlaceboDrug

    Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal strokeTime frame: From baseline (week 0) to end of study (up to 242 weeks or more)

Locations

633 sites in 25 countries. Site status is shown where the registry gives one.

  • Univ of Alabama Birmingham

    Birmingham, Alabama

  • Chambliss Clinical Trials LLC

    Montgomery, Alabama

  • Honor Health

    Scottsdale, Arizona

  • National Heart Institute Cal

    Beverly Hills, California

  • Valley Clinical Trials

    Covina, California

  • Scripps Wht Diab Inst La Jolla

    La Jolla, California

  • First Valley Medical Group

    Lancaster, California

  • Clinical Trials Research_Sacramento

    Lincoln, California

  • Torrance Clin Res Inst, Inc.

    Lomita, California

  • Pacific Clinical Studies

    Los Alamitos, California

  • Monterey Endocrine & Diabetes Institute, Inc

    Monterey, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • Desert Oasis Hlthcr Med Group

    Palm Springs, California

  • Western University of Health Sciences

    Pomona, California

  • Linda Vista Health Care Ctr

    San Diego, California

  • N America Res Inst - San Dimas

    San Dimas, California

  • Encompass Clinical Research_Spring Valley

    Spring Valley, California

  • Lundquist Inst.-Biom Inno-UCLA

    Torrance, California

  • Bridgeport Hospital

    Bridgeport, Connecticut

  • Innovative Research of W FL

    Clearwater, Florida

  • Florida Premier Cardiology

    Delray Beach, Florida

  • Fleming Island Center for Clinical Research

    Fleming Island, Florida

  • Life Spring Research Foundation LLC

    Miami, Florida

  • Oceane 7 Medical & Research Center, Inc.

    Miami, Florida

  • Reyes Clinical Research, Inc

    Miami, Florida

  • San Marcus Res Clin Miami Lakes

    Miami Lakes, Florida

  • Floridian Clinical Research, LLC

    Miami Lakes, Florida

  • Adult Medicine of Lake County, Inc

    Mt. Dora, Florida

  • Suncoast Clinical Research, Inc.

    New Port Richey, Florida

  • Center for Diab,Obes & Metab

    Pembroke Pines, Florida

  • Hanson Clinical Research Center

    Port Charlotte, Florida

  • Northeast Research Institute

    Saint Augustine, Florida

  • Cardio Partners Clin Res Inst

    Wellington, Florida

  • Endo Res Solutions Inc

    Roswell, Georgia

  • Atlanta Heart Specialists, LLC

    Tucker, Georgia

  • Rocky Mountain Diab&Osteo Ctr

    Idaho Falls, Idaho

  • Northwest Heart Clinical Research, LLC

    Arlington Heights, Illinois

  • Macoupin Research Group

    Gillespie, Illinois

  • Clinical Invest Special_Gurnee

    Gurnee, Illinois

  • Endeavor Health

    Skokie, Illinois

Showing 40 of 633 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.